In­ovio’s decades of shift­ing ex­tends to way­ward win­ter in pipeline, work­force thin­ning 

For more than four decades, In­ovio has at­tempt­ed to cre­ate med­i­cines and vac­cines for can­cer and in­fec­tious dis­ease. It’s been a long-stand­ing bat­tle yet to come to fruition, with an­oth­er round of pipeline re­fin­ing and lay­offs in 2023.

The Penn­syl­va­nia biotech put out word Tues­day morn­ing it will let go of 11% of its work­ers, or about two dozen peo­ple, and fo­cus its DNA med­i­cines de­vel­op­ment on HPV-as­so­ci­at­ed dis­eases, with two tri­al read­outs ex­pect­ed this quar­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER